Literature DB >> 30076267

Cognitive and behavioural changes in PLS and PMA:challenging the concept of restricted phenotypes.

Bálint S de Vries1, Laura M M Rustemeijer1, Leonhard A Bakker1,2, Carin D Schröder2,3, Jan H Veldink1, Leonard H van den Berg1, Tanja C W Nijboer2,4, Michael A van Es5.   

Abstract

OBJECTIVES: Cognitive and behavioural changes within the spectrum of frontotemporal dementia (FTD) are observed frequently in patients with amyotrophic lateral sclerosis (ALS). Whether these changes also occur in other forms of motor neuron disease (MND) is not well studied. We therefore systemically screened a large cohort of patients with primary lateral sclerosis (PLS) and progressive muscular atrophy (PMA) for cognitive and behavioural changes, and subsequently compared our findings with a cohort of patients with ALS.
METHODS: Using a set of screening instruments (Edinburgh Cognitive and Behavioural ALS Screen, ALS and Frontotemporal Dementia Questionnaire, Frontal Assessment Battery, and Hospital Anxiety and Depression Scale), the presence of cognitive and behavioural changes as well as anxiety and depression in 277 patients with ALS, 75 patients with PLS and 143 patients with PMA was evaluated retrospectively.
RESULTS: We found a high frequency of cognitive and behavioural abnormalities with similar profiles in all three groups. Subjects with behavioural variant FTD were identified in all groups.
CONCLUSIONS: The percentage of patients with PLS and PMA with cognitive dysfunction was similar to patients with ALS, emphasising the importance for cognitive screening as part of routine clinical care in all three patient groups. With a similar cognitive profile, in line with genetic and clinical overlap between the MNDs, the view of PLS as an MND exclusively affecting upper motor neurons and PMA exclusively affecting lower motor neurons cannot be held. Therefore, our findings are in contrast to the recently revised El Escorial criteria of 2015, where PLS and PMA are described as restricted phenotypes. Our study favours a view of PLS and PMA as multidomain diseases similar to ALS. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Mesh:

Year:  2018        PMID: 30076267     DOI: 10.1136/jnnp-2018-318788

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  10 in total

1.  Extra-motor cerebral changes and manifestations in primary lateral sclerosis.

Authors:  Eoin Finegan; Stacey Li Hi Shing; Rangariroyashe H Chipika; Kai Ming Chang; Mary Clare McKenna; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Niall Pender; Colette Donaghy; Siobhan Hutchinson; Russell L McLaughlin; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-07       Impact factor: 3.978

Review 2.  A novel variant in DYNC1H1 could contribute to human amyotrophic lateral sclerosis-frontotemporal dementia spectrum.

Authors:  Alexios-Fotios A Mentis; Dimitrios Vlachakis; Eleni Papakonstantinou; Ioannis Zaganas; George P Patrinos; George P Chrousos; Efthimios Dardiotis
Journal:  Cold Spring Harb Mol Case Stud       Date:  2022-03-24

Review 3.  Progress in Amyotrophic Lateral Sclerosis Gene Discovery: Reflecting on Classic Approaches and Leveraging Emerging Technologies.

Authors:  Samuel N Smukowski; Heather Maioli; Caitlin S Latimer; Thomas D Bird; Suman Jayadev; Paul N Valdmanis
Journal:  Neurol Genet       Date:  2022-04-27

Review 4.  Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan
Journal:  CNS Drugs       Date:  2021-05-15       Impact factor: 5.749

5.  Primary lateral sclerosis: consensus diagnostic criteria.

Authors:  Martin R Turner; Richard J Barohn; Philippe Corcia; John K Fink; Matthew B Harms; Matthew C Kiernan; John Ravits; Vincenzo Silani; Zachary Simmons; Jeffrey Statland; Leonard H van den Berg; Hiroshi Mitsumoto
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-02-06       Impact factor: 10.154

Review 6.  Moving Toward Patient-Tailored Treatment in ALS and FTD: The Potential of Genomic Assessment as a Tool for Biological Discovery and Trial Recruitment.

Authors:  Iris J Broce; Patricia A Castruita; Jennifer S Yokoyama
Journal:  Front Neurosci       Date:  2021-03-01       Impact factor: 4.677

7.  Parental and child adjustment to amyotrophic lateral sclerosis: transformations, struggles and needs.

Authors:  Marion Sommers-Spijkerman; Neele Rave; Esther Kruitwagen-van Reenen; Johanna M A Visser-Meily; Melinda S Kavanaugh; Anita Beelen
Journal:  BMC Psychol       Date:  2022-03-17

8.  Frontotemporal Dementia as a Possible Manifestation of Primary Lateral Sclerosis: A Case Report and Literature Review.

Authors:  Kevin Qosja; Nicole M Absar; Allen T Yu
Journal:  Case Rep Psychiatry       Date:  2022-03-04

Review 9.  Upper Motor Neuron Disorders: Primary Lateral Sclerosis, Upper Motor Neuron Dominant Amyotrophic Lateral Sclerosis, and Hereditary Spastic Paraplegia.

Authors:  Timothy Fullam; Jeffrey Statland
Journal:  Brain Sci       Date:  2021-05-11

10.  Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis.

Authors:  Katerina Placek; Michael Benatar; Joanne Wuu; Evadnie Rampersaud; Laura Hennessy; Vivianna M Van Deerlin; Murray Grossman; David J Irwin; Lauren Elman; Leo McCluskey; Colin Quinn; Volkan Granit; Jeffrey M Statland; Ted M Burns; John Ravits; Andrea Swenson; Jon Katz; Erik P Pioro; Carlayne Jackson; James Caress; Yuen So; Samuel Maiser; David Walk; Edward B Lee; John Q Trojanowski; Philip Cook; James Gee; Jin Sha; Adam C Naj; Rosa Rademakers; Wenan Chen; Gang Wu; J Paul Taylor; Corey T McMillan
Journal:  EMBO Mol Med       Date:  2020-12-03       Impact factor: 14.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.